Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $580000.0.

  • Zenas BioPharma's Other Accumulated Expenses rose 7469.88% to $580000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $580000.0, marking a year-over-year increase of 7469.88%. This contributed to the annual value of $249000.0 for FY2024, which is 13490.57% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Other Accumulated Expenses is $580000.0, which was up 7469.88% from $508000.0 recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Other Accumulated Expenses ranged from a high of $580000.0 in Q3 2025 and a low of $106000.0 during Q4 2023
  • For the 3-year period, Zenas BioPharma's Other Accumulated Expenses averaged around $359833.3, with its median value being $358000.0 (2024).
  • In the last 5 years, Zenas BioPharma's Other Accumulated Expenses soared by 13490.57% in 2024 and then skyrocketed by 7469.88% in 2025.
  • Over the past 3 years, Zenas BioPharma's Other Accumulated Expenses (Quarter) stood at $106000.0 in 2023, then soared by 134.91% to $249000.0 in 2024, then skyrocketed by 132.93% to $580000.0 in 2025.
  • Its Other Accumulated Expenses stands at $580000.0 for Q3 2025, versus $508000.0 for Q2 2025 and $384000.0 for Q1 2025.